Skip to content
OpenCapital
Get started

Avalo Therapeutics AVTX Q4 2024 Annual earnings

Reported April 4, 2025 · Before market open

Revenue$192.0KDiluted EPS-$7.95Miss by $8.53
EPS estimate$0.58

Next report

Aug 6, 2026 (In 3 weeks)
EPS estimate-$0.66

Financials

Q4 2024

Income statement

See full
Revenue$192.0K-66.4%
Operating income-$13.3M-73.8%
Net income-$35.3M-333%

Balance sheet

See full
Cash & equivalents$134.7M+1,685%
Total debt$918.0K-51.8%
Total equity$133.0M+1,721%
Total assets$150.7M+618%

Cash flow

See full
Operating cash flow-$15.0M-444%
CapEx-—
Free cash flow-$15.0M-444%

Valuation & ratios

Valuation

as of 12/31/24
See full
Market cap$77.74M+966%
Enterprise value-$56.03M-3,493%
P/S176.3×+173×

Profitability

See full
Operating margin-15,536.1%-17,275pp
Net margin-7,965.8%-10,750pp
FCF margin-11,123.8%-13,374pp

Returns & leverage

See full
Return on equity-50.1%—
Debt / equity0×-0.3×
Current ratio20×+18.1×

Versus estimates

Revenue

Q4 2025$59.0KIn line
Q4 2024$192.0K

Diluted EPS

Q1 2026-$0.98Beat by $0.02Q4 2025-$0.37Beat by $1.17Q3 2025-$2.19Miss by $0.52Q2 2025-$1.92Miss by $0.49Q1 2025-$1.25Miss by $0.18
Q4 2024-$7.95Miss by $8.53

Ask the moment Avalo Therapeutics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Avalo Therapeutics report Q4 2024 earnings?
Avalo Therapeutics (AVTX) reported Q4 2024 earnings on April 4, 2025 before market open.
What were Avalo Therapeutics's Q4 2024 revenue and EPS?
Avalo Therapeutics reported revenue of $192.0K and diluted EPS of $-7.95 for Q4 2024.
Did Avalo Therapeutics beat estimates in Q4 2024?
EPS missed the consensus estimate of $0.58 by $8.53.
How did Avalo Therapeutics's Q4 2024 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 66.4% from $571.0K a year earlier and diluted EPS declined 32.9% from $-5.98.
Where can I find Avalo Therapeutics's Q4 2024 SEC filings?
You can read the 10-K periodic report (0001628280-25-013986) directly on SEC EDGAR. The filing index links above go to sec.gov.